Cytologic Screening Programs

Comprehensive Cytopathology

Volumn , Issue , 2008, Pages 47-57

  Collaço, Luiz M ^a   Zardo, Lucilia ^b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955614842     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141604208-2.10003-X     Document Type: Chapter

References (77)

1. Anderson G.H., Flynn K.J., Hickey L.A., et al. A comprehensive internal quality control system for a large cytology laboratory. Acta Cytol 1997, 31:895-899.
2. Babes A. Diagnostic du cancer du col utérin par les frottis. PresseMedicale 1928, 36:451-454.
3. Papanicolaou GN. New cancer diagnosis. In: Proceedings of the Third Race Betterment Conference January 1928; Battle Creek, Michigan, Race Betterment Foundation, 528-534.
4. Papanicolaou G.N., Traut H.F. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941, 42:193-206.
5. Papanicolaou G.N. Atlas of Exfoliative Cytology 1954, Commonweath Fund University Press, Boston.
6. Lazcano-Ponce E., Alonso P., Ruiz-Moreno J.A., et al. Recomendations for cervical cancer screening programs in developing countries. The need for equity and technological development. Salud Publica de Mexico 2003, 45:449-462.
7. World Health Organization Cytological screening in the control of cervical cancer: Technical guidelines. Geneva 2 1988.
8. World Health Organization Cervical cancer screening in developing countries: report of a WHO consultation. Genebra 2002, 1-75.
9. Sankaranarayanan R., Budukh A.M., Rajkumar R. Effective screening programmes for cervical cancer in low-and middle-income developing countries. Bull World Health Organ 2001, 79(suppl):954-962.
10. World Cancer Report 2003 2003, IARC Press, Lyon. B.W. Stewart, P. Kleihues (Eds.).
11. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cancer worldwide. J Pathol 1999, 189:12-19.
12. International Agency for Research on Cancer IARC Handbooks of Cancer Prevention: Cervical Cancer Screening 2005, IARC, Lyon, 1-57.
13. Richart R.M. Task Force Two: Reasons for Regional I Differences in Prevalence of Cervical Lesions 2000, International Conference on the Fight Against Cervical Cancer, Chicago.
14. Waddell C. Glandular prediction: the pride and the prejudice. Cytopathology 2004, 15:177-180.
15. Koss L.G. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. JAMA 1989, 261:737-743.
16. Parkin D.M., Bray F. The burden of HPV-related cancers. Vaccine 2006, 24(Suppl 3):11-25.
17. Miller A.B., Anderson G., Brisson J., et al. Report of a National Workshop on Screening for Cancer of the Cervix. Can Med Assoc J 1991, 145(10):1301-1325.
18. Denny L. The prevention of cervical cancer in developing countries. BJOG 2005, 112:1204-1212.
19. Johannesson G., Geirsson G., Day N. The effect of mass screening in Iceland, 1965-1974, on the incidence and mortality of cervical carcinoma. Int J Cancer 1978, 21:418-425.
20. Hakama M. Trends in the incidence of cervical cancer in the Nordic countries. Trends in Cancer Incidence 1982, 279-292. Hemisphere Press, New York. K. In:Magnus (Ed.).
21. Laara E., Day N.E., Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987, 1:1247-1249.
22. Anderson G.H., Benedet J.L., LeRiche J.C. Invasive cancer of the cervix in British Columbia: A review of demographic and screening histories of 437 cases seen from 1985-1988. Obstet Gynecol 1992, 80(1):1-4.
23. Krane J.F., Granter S.R., Trask C.E., et al. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer 2001, 93:8-15.
24. International Agency for Research on Cancer (IARC). IARC confirms efficacy of cervix cancer screening for women 25-65 in reducing mortality. Press release no. 151. Lyon; 2004 [cited 2004 May 3]. Acessed on 2007 Mar 31 Available from:http://www.iarc.fr/ENG/Press_Releases/Summary.pdf.
25. Fahey M.T., Irwig L., Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995, 141:680-689.
26. Nanda K., McCrory D.C., Myers E.R., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000, 132:810-819.
27. Parikh S., Brennan P., Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 2003, 105:687-691.
28. Miller A.B. Quality assurance in screening strategies. Review. Virus Res 2002, 89(2):295-299.
29. Suba E.J. Crossing the quality chasm: a requirement for successful cervical cancer prevention in developing countries. Clin Lab Med 2004, 24:945-963.
30. Guidozzi F. Obstet screening for cervical cancer. Gynecol Surv 1996, 51:247-252.
31. Anderson G.H., Boyes D.A., Benedet J.L., et al. Organisation and results of cervical cytology screening programme in British Columbia, 1955-1985. BMJ 1988, 296:975-978.
32. Collaco L.M., de Noronha L., Pinheiro D.L., et al. Quality assurance in cervical screening of a high risk population: a study of 65,753 reviewed cases in Parana Screening Program, Brazil. Diagn Cytopathol 2005, 33:441-448.
33. Sankaranarayanan R., Thara S., Sharma A., et al. Accuracy of conventional cytology: Results from a multicentre screening study in India. J Med Screen 2004, 11:77-84.
34. Sankaranarayanan R., Gaffikin T.L., Jacob M., et al. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005, 89(suppl 2):S4-S12.
35. Zeferino L.C., Derchain S.F. Cervical cancer in the developing world. Best practice research. Clin Obstet Gynec 2006, 20:339-354.
36. Marcus A.C., Crane L.A., Kaplan C.P., et al. Improving adherence to screening follow-up among women with abnormal Pap smears: results from a large clinic-based trial of three intervention strategies. Med Care 1992, 30:216-230.
37. Garner D. Potencial limitations of screening programs. Task Force 13. International Consensus Conference on the Fight against Cervical Cancer. International Academy of Cytology. 2000.
38. Kirnbauer R., Booy F., Cheng N., et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992, 89:12,180-12,184.
39. Harro C.D., Pang Y.Y., Roden R.B., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001, 93:284-292.
40. Koutsky L.A., Ault K.A., Wheeler C.M., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347:1645-1651.
41. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
42. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6:271-278.
43. Muñoz N., Bosch F.X., Castellsagué X., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Inter J Cancer 2004, 111:278-285.
44. WHO. Report of the consultation on human papillomavirus vaccines. 2005; Geneva; 1-34. Acessed on 2007 Mar 31. Available from:http://www.who.int/vaccines-documents/DocsPDF05/816screen.pdf.
45. Parry J. Vaccinating against cervical cancer. Bull World Health Organ 2007, (2):85.
46. Harper D.M., Franco E.L., Wheeler C., et al. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
47. Pollack A.E., Balkin M., Edouard L., et al. Ensuring access to HPV vaccines through integrated services: a reproductive health perspective. Bull World Health Organ 2007, (1):85.
48. Goldie S.J., Kohli M., Grima D., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96:604-615.
49. Wright T.C., Cox J.T., Massad L.S. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol 2003, 1:295-304.
50. Bosch FX: Cervical cancer epidemiology and rationale for human papilomavirus (HPV) related preventive strategies. Twenty-first International Conference and Clinical Workshop Papilomavirus, 2004.
51. Franco E.L., Ferenckzy A. Is HPV testing with cytological triage a more logical approach in cervical cancer screening?. Lancet Oncol 2006, 7:527-529.
52. Girianelli V.R., Thuler L.C., Szklo M., et al. Comparison of human papillomavirus DNA tests, liquid-based cytology and conventional cytology for the early detection of cervix uteri cancer. Eur J Cancer Prev 2006, 15:504-510.
53. Diehl I.S., Prado R., Magna R.M. Organización Panamericana de la Salud. Manual de Procedimientos del Laboratório de Citologia. Red Panamericana de Citologia y Tamizaje 2002, 1-84. Red-PAC.
54. World Health Organization. Screening and early detection of cancer. Accessed on 2007 Mar 31. Available from:http://www.who.int/cancer/detection/en/.
55. Gondos B., King E.B. Significance of endometrial cells in cervicovaginal smears. Ann Clin Lab Sci 1977, 7(6):486-490.
56. Smith R.A., von Eschenbach A.C., Wender R., et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for early lung cancer detection. CA Cancer J Clin 2001, 51:38-75.
57. Fontana R.S., Sanderson D.R., Woolner L.B., et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991, 67(4 Suppl):1155-1164.
58. Petty T.L. The early identification of lung carcinoma by sputum cytology. Cancer 2000, 89(11 Suppl):2461-2464.
59. Wang K.K., Wongkeesong M., Buttar N.S. American Gastroenterological Association medical position statement: role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 2005, 128:1468-1470.
60. Dong Z., Tang P., Li L., Wang G. The strategy for esophageal cancer control in high-risk areas of China. Jpn J Clin Oncol 2002, 32(suppl 1):S10-S12.
61. Dawsey S., Shen Q., Nieberg R.K., et al. Studies of esophageal balloon cytology in Linxian, China. CA Epidem Biomar Prev 1997, 6:121-130.
62. National Cancer Institute. U.S. National Institutes of Health. Screening for bladder and other urothelial cancers. Acessed on 2007 Mar 31. Available at:http://www.cancer.gov/cancertopics/pdq/screening/bladder/HealthProfes sional/page2.
63. Burch J.D., Rohan T.E., Howe G.R., et al. Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Intern J Cancer 1989, 44(4):622-628.
64. Cole P., Hoover R., Friedell G.H. Occupation and cancer of the lower urinary tract. Cancer 1972, 29(5):1250-1260.
65. Brownson R.C., Chang J.C., Davis J.R. Occupation, smoking, and alcohol in epidemiology of bladder cancer. Am J Pub Health 1987, 77:1296-1300.
66. Anton-Culver H., Lee-Feldstein A., Taylor T.H. Occupation and bladder cancer risk. Am J Epidem 1992, 136:89-94.
67. Richard K., Dziura B., Hornish A. Cell block preparation as a diagnostic technique complementary to fluid-based monolayer cervicovaginal specimens. Acta Cytol 1999, 43(1):69-73.
68. Diaz-Rosario L.A., Kabawat S.E. Cell block preparation by inverted filter sedimentation is useful in the differential diagnosis of atypical glandular cells of undetermined significance in ThinPrep specimens. Cancer 2000, 90(5):265-272.
69. Massarani-Wafai R., Bakhos R., Wojcik E.M., et al. Evaluation of cellular residue in the ThinPrep PreservCyt vial. Diagn Cytopathol 2000, 23(3):208-212.
70. Longatto Filho A., Pereira S.M., Di Loreto C., et al. DCS liquid-based system is more effective than conventional smears to diagnosis of cervical lesions: study in high-risk population with biopsy-based confirmation. Gynecol Oncol 2005, 97(2):497-500.
71. Dahl M.B., Ejersbo D., Holund B. Cause and follow-up of inadequate cervical smears in the county of Funen. Ugeskr Laeger 2002, 164(37):4280-4283.
72. Alves V.A., Bibbo M., Schmitt F.C., et al. Comparison of manual and automated methods of liquid-based cytology. A morphologic study. Acta Cytol 2004, 48(2):187-193.
73. Nieminen P. Task force nine: Automated prescreening and rescreening. International Conference on the Fight against Cervical Cancer, Chicago 2000.
74. Engeland A., Haldorsen T., Tretli S., et al. Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. A collaborative study of the five Nordic Cancer Registries. APMIS 1993, 38(Suppl):1-124.
75. Hristova L., Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol 1997, 36(Suppl 9):1-60.
76. Cancer Incidence in Five Continents, vol. VII 1997, IARC Scientific Publications, No. 143. Lyon: IARC. D.M. Parkin, S.L. Whelan, J. Ferlay (Eds.).
77. Moller B., Fekjaer H., Hakulinen T., et al. Prediction of cancer incidence in Nordic countries up to the year 2020. Eur J Cancer Prev 2002, 11(Suppl 1):S1-S96.